ClinicalTrials.gg
RecruitingNCT07081984Updated Nov 24, 2025

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

A Phase 1 interventional study of therapeutic tumor vaccine in HPV 16+ Recurrent or Metastatic Cancer, HNSCC and Cervical Cancer, sponsored by Therorna. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Therorna · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
381st of 403
12 · median 90
Started
2025
with 61 others
Phase 1
93 of 487
47 open now
Primary completion
2026-09
later than 97 of 263 live
Registered
389th of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 381st largest by planned enrollment of the 403 interventional ones that give a count, is one of 62 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 97 of the 263 other live ones, and was the 389th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.

The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.

Read the detailed description

All potential study candidates will provide informed consent and undergo screening procedures to determine their study eligibility. After a screening period of up to 28 days, qualified patients will be enrolled to receive their assigned dose of TI-0093 injection. Patients will receive a total of five doses of TI-0093 administered muscularly on Day1, Day8, Day15, Day29 and Day43, respectively. Dose-limiting toxicities (DLTs) will be assessed for at least 28 days after the first dose of a given regimen. During the study, patients will be evaluated for safety, toxicity, immunogenicity, ORR, DOR, DCR, and PFS per protocol.

03

Conditions studied

  • HPV 16+ Recurrent or Metastatic Cancer
  • HNSCC
  • Cervical Cancer

Keywords

  • Therapeutic tumor vaccine
  • Circular RNA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following inclusion criteria to be eligible for participation in this study:

  1. The patient provides written for the study.
  2. Willing to comply with the visit plans, treatment plans, and other requirements of the study schedule.
  3. Previous HPV16+ solid tumors.
  4. 18 to 75 years of age at the time of informed consent.
  5. (ECOG) performance status 0 or 1 with no deterioration over the previous 2 weeks.
  6. Estimated of more than 12 weeks.
  7. Previous HPV16 positive head and neck, cervical and other carcinoma patients with recurrent or disease, who have progressed after standard therapies, or for whom no further standard therapies are available.
  8. Patients should have at least 1 at baseline according to the definition of RECISTv1.1.
  9. ≥ 1.5 ×10\^9/L, without the use of granulocyte colony stimulating factors such as filgrastim within 2 weeks prior to study treatment. count ≥ 100 × 10\^9/L without transfusion within 2 weeks (≤ 14 days) prior to study treatment. ≥ 9 g/dL without transfusion or erythropoietin within 2 weeks (≤ 14 days) prior to study treatment.
  10. and alanine aminotransferase ≤ 3 × (ULN) (patients with liver metastasis \< 5 × ULN), and total ≤ 1.5 × ULN (patients with Gilbert's Syndrome ≤ 3 × ULN).
  11. Adequate renal function defined by either a ≥ 45 mL/min (by Cockcroft-Gault formula) or serum creatinine \< 1.5 × ULN.
  12. ≤ 1.5 × ULN; activated partial thromboplastin time ≤ 1.5 × ULN; international normalized ratio ≤ 1.5 × ULN.
  13. ≥ 50% measured by echocardiogram.
  14. Females of and males whose partners are of childbearing potential agree to the use effective from signing informed consent form to 90 days after the last dose of TI-0093 injection. The test results of HCG of females with childbearing potential should be negative within 7 days prior to the first dose of TI-0093 injection.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following exclusion criteria cannot be enrolled:

  1. History of any therapeutic HPV vaccination. History of any live viral vaccine or attenuated therapies within 4 weeks prior to the first dose of TI-0093 injection.
  2. History of life-threatening or known to be allergic to any ingredients contained in the TI-0093 injection.
  3. Females who are pregnant or breastfeeding. Patients who plan to donate sperm or eggs from signing form to 90 days post the last dose of TI-0093 injection.
  4. Patients with underlying comorbidity will be excluded:

    A. Active known second , except for any of the following: basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer and non-muscle invasive bladder cancer, which were recovered from adequate clinical treatment, and other cancers treated by surgery alone whose disease-free survival were 5 years and above.

    B. Meningeal , spinal cord compression or symptomatic within 28 days prior to the first dose of TI-0093 injection (except for patients with prior brain metastases who were treated and clinically stable for 4 weeks without or antiepileptic drug treatment).

    C. History of severe pneumonia such as interstitial lung disease within 6 months prior to the first dose of TI-0093 injection.

    D. Major surgery within 4 weeks prior to the first dose of TI-0093 injection. E. Deep vein thrombosis or arterial embolism such as pulmonary embolism within 6 months prior to the first dose of TI-0093 injection.

    F. Active bleeding symptoms or diseases such as active hemoptysis, gastrointestinal bleeding and hemorrhagic gastric ulcer within 28 days prior to the first dose of TI-0093 injection.

    G. Alcohol dependence (averagely more than 2 units of alcohol per day (1 unit = 360 ml of beer, 45 ml of 40% liquor, or 150 ml of wine) which may affect safety assessment judged by the investigator. Drug abuse but unable to quit or mental disorders.

    H. Patients with active disease or symptoms that required systemic use of pharmacologic dose of corticosteroid and/or within 4 weeks prior to the first dose of TI-0093 injection. Exceptions are patients with vitiligo, resolved asthma/atopy, and type 1 diabetes mellitus or hypothyroidism that can be managed by replacement therapy.

    I. Severe or uncontrolled systemic diseases above:

    1. Grade 2 and above myocardial infarction, grade 2 and above myocardial ischemia, or grade 2 and above heart failure based on (NYHA) classification within 6 months prior to the first dose of TI-0093 injection. Arrhythmia such as ≥ 480ms needs to be treated and uncontrolled hypertension during the screening period.
    2. Any active or uncontrolled infection such as uncontrolled diabetes (defined as ≥ 7.5%), asthma, clinically active diverticulitis, abdominal abscess or gastrointestinal obstruction during the screening period.
    3. Active (both hepatitis B virus surface antigen being positive and hepatitis B virus carriers with a viral load > 200 IU/ml), active (both HCV antibody and RNA testing being positive), positive for treponema pallidum in serum or active tuberculosis during the screening period.
    4. Known positive test results for (HIV) or acquired immune deficiency syndrome (AIDS). Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
    5. History of gastrointestinal perforation, gastrointestinal fistula or female reproductive tract fistula within 6 months prior to the first dose of TI-0093 injection. Except for those recovered after treatment judged by the investigator.
    6. Pleural effusion, ascites or pericardial effusion requires puncture aspiration or drainage within 2 weeks prior to the enrollment.
  5. Grade 3 and above immune-related AEs or any immune-related AE lead to discontinuation of prior immunotherapy.
  6. Any previous AE has not been improved to Grade 1 and below (except for patients with hair loss, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy or other AEs with no safety risk judged by the investigator).
  7. Asplenia or insufficiency of spleen function caused by infarct of spleen or thrombosis of splenic vein.
  8. Systemic treatment with corticosteroids (≥ 10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days prior to the first dose of TI-0093 injection.
  9. for any previous immunomodulatory drugs such as thymosin, interleukin-2, and interferon: last treatment is within 4 weeks prior to prior to the first dose of TI-0093 injection.
  10. Washout period for any previous anticancer therapy prior to the first dose of TI-0093 injection:

    1. Last treatment is within 4 weeks for chemotherapy, biologic therapy, target therapy or immunotherapy.
    2. Last treatment is within 2 weeks for radiotherapy, endocrine therapy or oral fluorouracil drugs.
    3. Last treatment is within 7 days for anticancer Chinese medicine.
    4. Last treatment is within 6 weeks for nitrosoureas and mitomycin.
  11. Last treatment with product is within 5 half-lives or 4 weeks (which is longer).
  12. Any other disease or abnormality in laboratory parameters, which in the judgment of the investigator might compromise the safety of the patient or integrity of the study, interfere with the patient participation in the trial or compromise the trial objectives.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    TI-0093 injection

    Therapeutic tumor vaccine: TI-0093 injection. Different dose levels of TI-0093 injection. Route of administration: Muscle

    Biological: therapeutic tumor vaccine

Interventions

  • Biologicaltherapeutic tumor vaccine

    TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    The safety profiles of TI-0093 injection will be assessed in terms of severity, seriousness, frequency of AEs, laboratory results, vital signs, physical examinations, and 12-lead electrocardiogram of the patients enrolled in the study.

    Time frame: From enrollment to 28 days post the last dose of TI-0093 injection

  2. DLTs

    DLTs will be assessed for at least 28 days after the first dose TI-0093 injection of a given regimen. Toxicities will be assessed by the National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5.0.

    Time frame: From enrollment to 3 months.

  3. RP2D

    The RP2D will be determined based on the observation of MTD.

    Time frame: From enrollment to 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Confidentiality based on clinical development strategies of TI-0093 injection, IPD sharing will not be planned.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 10 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 24, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Sep 20, 2026
CompletionEst.
Jul 31, 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081984
Lead sponsor
Therorna
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Nov 11, 2025
Primary completion
Sep 20, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Ye Guo
Contact
pattrickguo@gmail.com
0086-457-13501678472
The Drug Clinical Trial Institution of Shanghai East Hospital
Contact
shdfgcp@163.com
021-38804518-28329 ext. 021-2033453

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion